Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07607483
PHASE1

A Study of LY4065967 in Healthy Participants

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to compare 3 different forms of LY4065967 - a tablet and 2 types of capsule - to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 7 weeks and will include 3 stays in the Clinical Research Unit (CRU). Each stay will last 3 nights.

Official title: A Phase 1, Randomized, Open-Label, Crossover Study to Investigate the Relative Bioavailability of LY4065967 Formulations in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2026-06

Completion Date

2026-07

Last Updated

2026-05-26

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

LY4065967 Tablet

Administered orally

DRUG

LY4065967 Formulated Capsule

Administered orally

DRUG

LY4065967 Capsule

Administered orally

Locations (2)

Fortrea Clinical Research Unit

Daytona Beach, Florida, United States

Fortrea Clinical Research Unit

Dallas, Texas, United States